Viant Stock Slips Before the Open as Its CTV News Bet Faces a Pre-Holiday Test

Viant Stock Slips Before the Open as Its CTV News Bet Faces a Pre-Holiday Test

May 22, 2026

New York, May 22, 2026, 08:05 EDT

• Viant was quoted at $10.96 in premarket trading, down 0.36%, after closing Thursday at $11.00.
• The company’s newest catalyst is a May 20 partnership with Ad Fontes Media for connected-TV news ad targeting.
• Fresh Form 4 filings showed additional insider-related sales under a prearranged trading plan.

Viant Technology Inc. shares edged lower before the U.S. open on Friday, giving back a sliver of Thursday’s gain as investors weighed a new connected-TV news product against a still-small stock float and fresh insider-sale filings. Market data showed DSP at $10.96 at 7:12 a.m. EDT, down 0.36% from its $11.00 close on Thursday.

The timing matters. Viant, a Nasdaq-listed demand-side platform, or DSP — software that advertisers use to buy digital ads automatically — is trying to turn connected TV into a bigger earnings story. Connected TV, or CTV, means streaming video watched through internet-connected televisions or devices.

On May 20, Viant said it had partnered with Ad Fontes Media to let advertisers target CTV news inventory using reliability and political-bias data tied to IRIS_ID, a content-identification system used in streaming advertising. Viant said the offering lets advertisers buy against “trusted news programming” at the content level, rather than only by app or publisher. Viant

The pitch comes as political and news advertising grows more sensitive before the U.S. midterm cycle. Ad Fontes Chief Executive Vanessa Otero said advertisers “don’t need to avoid news,” but need better tools to judge it. Viant said the integration is already available across live news programming from leading CTV publishers. Viant

The stock’s broader backdrop is less dramatic. The Nasdaq Composite rose 0.09% to 26,293.10 on Thursday, while Viant closed up 0.46%. U.S. equity markets were set to trade on a normal Friday schedule before Nasdaq closes Monday, May 25, for Memorial Day. FRED

Recent filings added a small wrinkle. A Form 4 filed May 21 for Chief Operating Officer Christopher Vanderhook showed indirect sales of Class A shares through Capital V LLC on May 19, May 20 and May 21, after related Class B unit exchanges. The filing said the sales were made under a Rule 10b5-1 plan, a prearranged plan that lets insiders sell stock under set conditions.

Viant’s last earnings report gave bulls more to work with. The company reported first-quarter revenue of $88.5 million, up 25% from a year earlier, while its net loss narrowed to $2.2 million. Adjusted EBITDA, a profit measure that strips out interest, taxes, depreciation and some other costs, rose 81% to $9.8 million. Chief Executive Tim Vanderhook called it “record first quarter results.” Viant

The company guided for second-quarter revenue of $98.5 million to $101.5 million and adjusted EBITDA of $13 million to $14 million. Chief Financial Officer Larry Madden said Viant expected to “accelerate top-line growth” through 2026, citing CTV demand, ViantAI adoption and its sales pipeline. Viant

Part of that case rests on TVision Insights, which Viant acquired earlier this month. TVision measures whether viewers are actually present and watching ads, using signals such as eyes-on-screen attention and co-viewership. Vanderhook said “attention is the only currency” that matters in TV; TVision CEO Yan Liu put it more bluntly: “if someone isn’t watching your ad, it didn’t happen.” Viant

Analysts have mostly stayed constructive. B. Riley analyst Naved Khan raised his price target on Viant to $18 from $17 and kept a Buy rating after the first-quarter report, saying the quarter was strong and the stock’s risk/reward remained attractive. D.A. Davidson analyst Tom White separately raised his target to $16.50 from $16 and kept a Buy rating. TipRanks

The competitive read-through is mixed. Viant sits on the advertiser-buying side of ad tech, where The Trade Desk is the larger benchmark; that company has faced investor concern over slower growth and pressure from Amazon in connected TV. On the supply side, Magnite markets itself as an independent platform that helps media owners sell premium inventory, including CTV. MarketWatch

But the downside is plain enough. The Ad Fontes partnership may not change near-term spending if brands still avoid political news inventory, and the TVision deal has to be integrated without slowing Viant’s own platform work. Viant also warned that the programmatic ad market could develop more slowly than expected and that privacy rules, AI risks and competition could hit results.

Stock Market Today

  • GSK Shares Rise on Orphan Drug Status and $10.6 Billion Nuvalent Oncology Deal
    June 12, 2026, 9:13 AM EDT. GSK shares rose 1.32% after momelotinib earned Orphan Drug Designation from the US FDA and European Medicines Agency for VEXAS syndrome, a rare inflammatory disorder. This designation offers development incentives but does not authorize sales. The boost follows GSK's $10.6 billion acquisition of Nuvalent, adding late-stage lung cancer drugs zidesamtinib and neladalkib, with FDA decisions due by November 2026. GSK posted 5% sales growth in Q1 2026, driven by Specialty Medicines up 14% and oncology up 28%. The company aims for 3%-5% turnover growth and 7%-9% profit rise in 2026 but faces patent expiry and integration risks from the Nuvalent deal. Investors focus on upcoming ATLAS trial data and regulatory milestones for pipeline momentum.